Sage/Biogen Zuranolone Study Shows More Efficacy, But Higher Toxicity
Commercial Prospects Still Murky
Executive Summary
Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.
You may also be interested in...
Zuranolone Launch Requires Sage To Shift The Way Doctors Treat Depression
CEO Barry Greene and team spoke with Scrip about Sage and Biogen’s focus on short-term, episodic dosing, and said doctors and payers – pending zuranolone’s approval – are responding to the sales pitch.
Lecanemab Filing Complicates Biogen's Hunt For New CEO
Lecanemab is now filed for accelerated approval with the US FDA, but the wait for a Phase III readout could impact the hunt for Biogen’s next CEO.
Sage/Biogen Depression Data Likely To Prolong Commercial Debate
Data from the Phase III CORAL study of zuranolone showed the drug missing efficacy at day 15, which may dampen its appeal in the real-world setting.